Transdermal estrogen is a form of estrogen therapy delivered through the skin, bypassing the liver, unlike oral pills.
Transdermal estradiol is a bioidentical estrogen delivered via patches, gels, sprays, or lotions, indicated for treatment of moderate-to-severe vasomotor symptoms, vulvovaginal atrophy, hypoestrogenism, and prevention of postmenopausal osteoporosis.
Patches (e.g., Vivelle-Dot, Climara) – applied to skin, changed 1–2x/week Gels (e.g., EstroGel, Divigel) – applied daily, usually to arm or thigh Sprays (e.g., Evamist) – applied to inner forearm daily Creams – less standardized dosing
Common uses Menopausal symptom relief (hot flashes, night sweats, vaginal dryness) Hormone therapy for transgender women Osteoporosis prevention Hypogonadism
Advantages over oral estrogen Lower risk of blood clots (VTE) and stroke — a significant benefit
Observational data consistently show that transdermal estrogen confers little to no increased VTE risk compared to nonusers, whereas oral estrogen significantly increases VTE risk. More stable hormone levels (no first-pass liver metabolism) Lower impact on triglycerides and clotting factors
Considerations Skin irritation at application site is possible Transfer risk to others (especially with gels/sprays
Still carries estrogen-related risks (breast cancer, cardiovascular depending on individual history
Usually combined with a progestogen if a uterus’s is present, to protect the uterine lining
Estrogen delivered parenterally by means of a transdermal patch avoids first pass hepatic metabolism, and carries a lower risk of cardiovascular thromboembolic complications than orally administered estrogen and in a controlled trial with locally advanced prostate cancer transdermal estradiol was non-inferior to LHRH agonists for three year metastasis free survival and a lower incidence of hot flashes, but a higher incidence of gynecomastia (STAMPEDE-1 and PATCH investigators).
Starting dose is typically 0.025 mg/day, with dose adjustment guided by clinical response.
Patches are applied to clean, dry skin on the lower abdomen or upper buttock with site rotation.
Reassessment for continued need is recommended at 3- to 6-month intervals.
Advantages Over Oral Estrogen
The transdermal route avoids first-pass hepatic effects, which has several clinically meaningful implications:
Transdermal estrogen avoids the increases in triglycerides, C-reactive protein, and sex hormone binding globulin seen with oral formulations.
Data suggests lower stroke risk with transdermal versus oral estrogen.
The American College of Obstetricians and Gynecologists (ACOG) recommends that clinicians consider the thrombosis-sparing properties of transdermal estrogen when prescribing, particularly for women with obesity, immobilization, or other VTE risk factors.
Transdermal preparations were not associated with increased VTE, in contrast to oral formulations.
Transdermal estradiol is contraindicated in the setting of:
Undiagnosed abnormal genital bleeding
Known or history of breast cancer or estrogen-dependent neoplasia
Active or history of DVT, PE, stroke, or MI
Known thrombophilic disorders (protein C, protein S, or antithrombin deficiency)
Hepatic impairment or disease
Hypersensitivity to the product
Estrogen-alone therapy carries increased risks of endometrial cancer in women with a uterus, stroke, DVT, and probable dementia in women 65+years.
A progestogen should be added for women with an intact uterus to reduce endometrial cancer risk.
Micronized progesterone may carry lower risks of VTE and breast cancer compared to synthetic progestins.
For women with an intact uterus, a progestogen must be added.
Observational data suggest that micronized progesterone has a more favorable safety profile than synthetic progestins regarding VTE, breast cancer risk, and lipid effects.
The combination of transdermal estradiol (<50 μg/day) with micronized progesterone appears to be the safest regimen with respect to thrombotic and stroke risk.